New Two-Target CAR-T therapy tested in kids with tough leukemia
NCT ID NCT06559189
Summary
This study is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on leukemia cells. It aims to find a safe dose and see if it can help children and young adults (3 months to 30 years old) whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments. The main goal is to see how well the treatment is tolerated and if it can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.